Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors.
The success of tumor oncolytic virotherapy is limited by the poor penetration of virus in tumors. Interstitial collagen fibers and the narrow spacing between cancer cells are major barriers hindering the movement of large viral particles. To bypass the cellular barrier, we tested the hypothesis that the void space produced by cancer cell apoptosis enhances the initial spread and efficacy of oncolytic herpes simplex virus (HSV). In mice with mammary tumors, apoptosis was induced by doxycycline-regulated expression/activation of CD8/caspase-8, paclitaxel, or paclitaxel plus tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In both collagen-poor and collagen-rich tumors, apoptosis or necrosis increased the initial intratumoral spread of HSV. Compared with the isolated pattern of HSV infection generally located in the center of control tumors, apoptosis induction and a single i.t. injection of virus produced an interconnected and diffuse pattern of infection, which extended from the tumor center to the periphery. This interconnected pattern of viral infection correlated with the formation of void spaces and channel-like structures in apoptosis-rich tumor areas. We also show that the i.t. injection of HSV after caspase-8 activation or paclitaxel-TRAIL pretreatment retards tumor growth, whereas HSV administration before tumor cell death induction did not improve therapeutic efficacy. Hence, our findings show that the induction of cancer cell death before the injection of oncolytic HSV enhances intratumoral virus delivery/penetration and antitumor efficacy.
Nagano
Satoshi
S
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Perentes
Jean Yannis
JY
Jain
Rakesh K
RK
Boucher
Yves
Y
D017209:Apoptosis; D016827:CD8 Antigens / Q000096:biosynthesis; D016923:Cell Death; D045744:Cell Line, Tumor; D003094:Collagen / Q000378:metabolism; D006801:Humans; D009336:Necrosis; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D017239:Paclitaxel / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D018139:Simplexvirus / Q000378:metabolism*; D018874:Spheroids, Cellular / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D014407:Tumor Cells, Cultured
D016827:CD8 Antigens; D053221:TNF-Related Apoptosis-Inducing Ligand; D003094:Collagen; D017239:Paclitaxel